BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

B.Braun Medical Renal Therapies Division Announces Availability of Advanced Apheresis Therapy System


7/14/2011 10:02:16 AM

BETHLEHEM, Pa., July 14, 2011 /PRNewswire/ -- The Renal Therapies Division ofB. Braun Medical Inc. (B. Braun) announced today the availability of the Plasmat Futura System for H.E.L.P.® LDL Apheresis therapy. This addition to B. Braun's existing H.E.L.P.® therapy provides a more easy-to-use system for clinicians to administer the most effective care to patients with severe hypercholesterolemia.

(Logo: http://photos.prnewswire.com/prnh/20081022/NYW008LOGO )

H.E.L.P.® therapy (Heparin-induced Extracorporeal Lipoprotein Precipitation) is a blood cleansing procedure for the long-term management of patients with severe, congenital lipid disorders that cannot be adequately treated with diet modification or drugs.

"The addition of the Plasmat Futura Apheresis system to our existing H.E.L.P.® therapy system exemplifies B. Braun's commitment to providing clinicians with innovative systems that help get their jobs done with more convenience and flexibility," said Samuel Amory, Vice President, Medical Technology Division for B. Braun Medical Inc. "LDL Apheresis therapy is a complex therapy and the Plasmat Futura helps to streamline treatment."

Designed to be compact and easy to use, the Plasmat Futura system provides built-in convenience for maximum mobility and flexibility. In addition, the Plasmat Futura features a state-of-the-art user interface and does not require an on-site water treatment system, both improvements over the previous H.E.L.P.® system.

"The Plasmat Futura LDL Apheresis machine is the first promising procedure that has drastically cut my LDL by more than 60 percent," said Patrika Wallach-Knickle, a patient of Massachusetts General Hospital. "All it requires is a commitment of two mornings a month to sit and relax while the machine does the work. This small commitment is nothing compared to the benefits of seeing my small child grow up. I am very grateful for the B. Braun Plasmat Futura LDL Apheresis machine."

For more information on the Plasmat Futura System for H.E.L.P.® Apheresis therapy or to request a demo please visit www.bbraunusa.com or call 800-848-2600.

About B. Braun

B. Braun is a leading manufacturer of infusion therapy and pain management products with an environmentally-friendly focus. Guided by the company's "Sharing Expertise®" philosophy, B. Braun addresses the critical issues of infection prevention, medication safety and environmental responsibility by promoting best practices that help clinicians reduce medication errors, prevent healthcare-acquired infections (HAIs) and achieve sustainability objectives.

Consistently recognized by Frost & Sullivan and KLAS for its medical technology and support services, B. Braun employees share their knowledge with colleagues and customers to improve working processes in hospitals and medical practices and to enhance the safety of patients and healthcare professionals. For more information, call 800-227-2862, e-mail us at inquiry.us@bbraun.com or visit B. Braun at www.bbraunusa.com.

SOURCE B. Braun Medical Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES